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CObjective: To evaluate the cost-effectiveness of adjuvant FOLFOX ther-
apy versus 5-fluorouracil/leucovorin (FU/LV) for patients with stage III
colorectal cancer. Methods: We performed the cost-effectiveness of
FOLFOX comparedwith standard FU/LV treatment by the retrospective
analysis of patient-level data from the randomized controlled Multi-
center International Study of Oxaliplatin, 5-Fluorouracil, and Leuco-
vorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial. Pre-
dicted mean time spent in each disease state was calculated by our
statistical model, which takes into account the cure rate and treats
death from causes other than colon cancer as a competing risk. We
performed this analysis from the perspective of the health-care payer.
Using a time horizon of 30 years, both cost and effectiveness were
discounted by 3% per year. Results: Estimated cure rates for colon can-
er were 0.715 (FOLFOX) and 0.622 (FU/LV). Estimated medical costs of
OLFOX were JPY 3.1 million (USD 34,000) compared with JPY 1.9 mil-
ion (USD 22,000) of FU/LV. The mean estimated quality-adjusted life- O
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oi:10.1016/j.jval.2011.10.006ear was 9.83 with FOLFOX and 9.07 with that of FU/LV. The incremen-
al cost-effectiveness ratio of FOLFOX was JPY 1.5 million (USD 17,000)
er quality-adjusted life-year compared with FU/LV, which was sup-
orted by sensitivity analysis. Even if we assume that Japanese out-
omeswere better than those reported by theMOSAIC trial, whichwould
educe the difference between cure rates for each treatment to 5%, the
ncremental cost-effectiveness ratio remained below 5.0 million (USD
6,000) per quality-adjusted life-year. Conclusions: Adjuvant FOLFOX is
cost-effective treatment for stage III colon cancer in Japan compared
ith FU/LV therapy. Even when parameters were changed to reflect
maller improvements with FOLFOX, the conclusion is the same.
eywords: adjuvant drug therapy, colon cancer, cost-effectiveness,
OLFOX regimen, oxaliplatin.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
After lung and stomach cancer, colon cancer is the third leading
cause of death from malignant neoplasm in Japan. Age-adjusted
mortality for colon cancer is 12.5 deaths per 100,000 for men and
8.6 deaths per 100,000 for women. Although this rate has de-
creased from its peak around 2000, more than 28,000 people died
from colon cancer in 2009 [1]. Thus, colorectal cancer remains an
important public health issue.
Surgery and radiation therapy are standard treatments for
early-stage colon cancer; however, to reduce the risk of recurrence
and extend survival, chemotherapy may be administered as adju-
vant therapy to inhibit residual micrometastases in lymph nodes
and elsewhere in the body [2]. A pooled analysis of randomized
controlled trials (RCTs) showed that combined 5-fluorouracil/leu-
covorin (FU/LV) treatment reduced recurrence by 35% and death
by 22% after potentially curative resection of colon cancer com-
pared with no treatment [3]. FU/LV was shown to be superior to
other regimens, such as the lomustine, vincristine, and 5-FU reg-
imen [4] and the FU and levamisole regimen [5]; thus, FU/LV be-
came the standard adjuvant chemotherapy regimen for colon can-
cer. FU/LV adjuvant therapy is also the standard care in Japan.
* Address correspondence to: Takeru Shiroiwa, Department of B
-1-1, Noji-higashi, Kusatsu, Shiga 525-8577, Japan.
E-mail: t.shiroiwa@gmail.com.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.The FOLFOX regimen for metastatic colorectal cancer consists
of oxaliplatin, a platinum-based anticancer drug, combined with
FU/LV. RCTs have demonstrated that the FOLFOX regimen pro-
longs progression-free survival and overall survival (OS) compared
with FU/LV for patients with metastatic disease [6]. In addition,
FOLFOX is superior to FU/LV as an adjuvant therapy [7,8]. The
Multicenter International Study of Oxaliplatin, 5-Fluorouracil, and
Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
trial reported that FOLFOX improves the adjuvant treatment of
colon cancer [7]. In the MOSAIC trial, the 3-year disease-free sur-
vival (DFS) ratewas 78.2% for patients receiving FOLFOX and 72.9%
for those receiving FU/LV (hazard ratio for recurrence 0.77;
P 0.002). At 5 years, the DFS was 73.3% in the FOLFOX group and
7.4% in the FU/LV group. In patients with stage III cancer, the
-year OS was 72.9% in the FOLFOX group and 68.7% in the FU/LV
roup (hazard ratio 0.80; P  0.023) [9].
Some studies [10–12] have suggested that FOLFOX is a cost-
ffective treatment compared with FU/LV; however, some Jap-
nese oncologists believe that the recurrence rate for colorectal
ancer is lower in Japan than in European and North American
ountries. They therefore tend to be reluctant to use adjuvant
OLFOX therapy because they believe that Japanese patients
ill not benefit from adjuvant FOLFOX as much as patients who
dical Sciences, College of Life Sciences, Ritsumeikan University,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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256 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 5 5 – 2 6 0participated in the MOSAIC trial. This is complicated by the
issue of heterogeneity of clinical outcomes or how to extrapo-
late results from a large multinational RCT to cost-effectiveness
analyses in each country. If the results of a multinational RCT
are applied to economic evaluations, then heterogeneity of clin-
ical outcomes should be taken into account. The present study
focused on this theme. To reflect heterogeneity of baseline out-
comes and clinical benefit from FOLFOX and to extrapolate the
survival curve more appropriately, we used an elaborated sta-
tistical model that can account for cure rate; few others have
taken advantage of this model. With this statistical model, we
performed an economic evaluation of adjuvant FOLFOX therapy
for patients with stage III colorectal cancer based on patient-
level data from the MOSAIC trial.
Methods
Chemotherapy regimens
We retrospectively analyzed patient-level data from the multina-
tional randomized controlled MOSAIC trial. We used the data of pa-
tient characteristics, DFS, andOS at 3 years, aswell as dose of oxalip-
latin.
In theMOSAIC trial, stage II and stage III patientswere random-
ized to one of two treatment groups: FOLFOX, which consisted of
12 cycles of oxaliplatin (85mg/m2 intravenous infusion) on day 1 of
the 2-week cycle, LV (200 mg/m2 intravenous infusion) on days 1
nd 2, and 5-FU (400 mg/m2 bolus intravenous injection followed
by 600mg/m2 continuous infusion for 22 hours) on days 1 and 2, or
U/LV, which was the same regimen as FOLFOX treatment, but
ithout oxaliplatin.
Table 1 – Breakdown of chemotherapy costs.
Unit cost (JPY)
Outpatient chemotherapy
Granisetron 3 mg 5494
Dexamethasone 3.3 mg (vial) 195
Dexamethasone 3.3 mg (tablet) 6
Outpatient service fee 700
IV drip fee 980
Preparation in sterile environment 500
Outpatient chemotherapy 5500
Prescription fee 680
Diagnositc imaging
Chest CT scan 6600
Abdominal CT scan 6600
Pelvic CT scan 6600
CT scan diagnostic fee 4500
Blood test
Blood drawing fee 180
Peripheral blood tests fee 210
Peripheral blood tests diagnostic fee 1250
Biochemical tests fee 1230
Biochemical tests diagnostic fee 1440
Tumor maker tests fee 4000
Pharmacy costs
Pharmacist’s fee 400
Dispensing fee 100
Management of drug history 300
Drug information providing fee 150CT, computed tomography; FU/LV, 5-fluorouracil/leucovorin; JPY, JapanesTheMOSAIC trial enrolledpatientswithstage II andstage III colon
ancer; however, we assumed that FOLFOX therapy would be used
rimarily for patients with stage III cancer in Japan. Therefore, we
imited the target population to the stage III colon cancer intent-to-
reat subpopulation, and patients who did not receive even a single
ose of the predetermined chemotherapy protocol were excluded.
he intent-to-treat subpopulation (stage III) from the MOSAIC trial
sed in our analysis was FOLFOX (n  672) and FU/LV (n  675). De-
ographic characteristics of our targeted population were the same
s those reported by theMOSAIC trial; median agewas 60 years, and
he ratio of male and female was 1:1.
Framework of economic analysis
We performed a cost-effectiveness analysis of FOLFOX adjuvant
chemotherapy compared with FU/LV for the treatment of stage
III colon cancer. Our analysis was based on recommendations of
the Panel on Cost-Effectiveness in Health and Medicine [13].
Quality-adjusted life-years (QALYs) were used to calculate the
incremental cost-effectiveness ratio (ICER).
We considered three conditions: DFS, metastatic recurrence,
and death. The mean time spent in each state was estimated by
methods described in the “Statistical Analysis” section. Utility
scores were 0.8 (DFS), 0.6 (metastatic recurrence), and 0 (death)
based on a Japanese study that measured general population
utility scores of colorectal cancer by using time trade-off and
standard gamble methods [14].
This cost-effectiveness analysis was performed from the
perspective of the health-care payer and included only direct
medical costs, not indirect costs (e.g., productivity costs). Using
a time horizon of 30 years, both cost and effectiveness were
Number (per month) Price (JPY per month)
FOLFOX FU/LV FOLFOX FU/LV
45,000 32,000
2 0 10,988 0
6 6 1170 1170
64 0 378 0
4 4 2800 2800
4 4 3920 3920
4 4 2000 2000
4 4 22,000 22,000
2 0 1360 0
4100 4100
1 of 6 1 of 6 1100 1100
1 of 6 1 of 6 1100 1100
1 of 6 1 of 6 1100 1100
1 of 6 1 of 6 750 750
8700 8700
2 2 360 360
2 2 420 420
1 1 1250 1250
1 1 1230 1230
1 1 1440 1440
1 1 4000 4000
1900 0
2 0 800 0
2 0 200 0
2 0 600 0
2 0 300 0e yen; IV, intravenous.
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257V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 5 5 – 2 6 0discounted by 3% per year. Results were subjected to sensitivity
analysis.
Medical resource use and costs
All costs are expressed in Japanese yen (JPY) and US dollars (USD)
using an exchange rate of USD 1  JPY 90 (as of June 2010). Indi-
vidual costs of oxaliplatin treatment until completion or termina-
tion of treatment, estimated by multiplying patient dose by the
price of oxaliplatin, were JPY 70,284 (USD 780) for 100 mg and JPY
38,142 (USD 420) for 50 mg. Because patient-level data were not
available for FU/LV consumption, we simply added the cost of
FU/LV treatment, JPY 120,000 (USD 1300) per month multiplied by
FU dose intensity. As l-LV (isovorin) 100 mg/m2 is used instead of
V (leucovorin) 200mg/m2 in Japan, chemotherapy costs were cal-
culated on the basis of l-LV.
For adjuvant therapy costs, we also added the costs of outpa-
tient chemotherapy (JPY 45,000 [USD 500] per month for FOLFOX
and JPY 32,000 [USD 350] permonth for FU/LV), diagnostic imaging
(JPY 4100 [USD 45] per month), laboratory tests (JPY 8700 [USD 97]
per month), and pharmacy (JPY 1900 [USD 21] per month for
FOLFOX) (Table 1) [15]. After the completion of adjuvant chemo-
therapy, disease-monitoring costs (JPY 7000 [USD 80]) were also
included for 5 years, following the Japanese guidelines for colorec-
tal cancer.
Costs of metastasis were calculated on basis of the following
scenarios [15,16]: 1) JPY 2.0 million to JPY 2.5 million (USD 22,000–
Fig. 1 – Estimated cumulative incidence function curves: (A)
FOLFOX and (B) 5-fluorouracil/leucovorin (FU/LV). DFS,
disease-free survival.USD 28,000) per year for FOLFOX plus bevacizumab as first-linechemotherapy and FOLFIRI as second-line therapy; 2) JPY 2.5 mil-
lion to JPY 3.5 million (USD 28,000–USD 39,000) per year for
FOLFOX plus bevacizumab as first-line chemotherapy, FORFIRI as
second-line chemotherapy, and cetuximab as third-line chemother-
apy;or3) JPY1.0million to JPY1.5million (USD11,000–USD17,000) for
FOLFOX as first-line chemotherapy and FORFIRI as second-line che-
motherapy without monoclonal antibody therapy. We used JPY 2.0
million per year for our base-case analysis because bevacizumab or
cetuximab isadministered tomanypatientswithmetastatic colorec-
tal cancer. This cost was subject to sensitivity analysis. Adverse
event (AE) costswere not included in the base-case analysis, because
costswere unclear and the difference in costswasnot expected to be
large. AE costs were also subject to sensitivity analysis.
Costs were calculated for 2010 according to the social insur-
ance reimbursement schedule [15] and drug tariff [16] of the fee-
for-service system in Japan,which excludes inpatient treatment at
large hospitals. Censored data were considered to calculate mean
cost per patient, according to the method of Lin et al. [17]. Confi-
dence intervals for mean costs were obtained by the bootstrap
method.
Statistical analysis
Although some patients with colon cancer experience metastatic
recurrence, some cancers are completely cured without recur-
rence. Therefore, a simple parametric survival analysis cannot ad-
equately predict patient prognosis. We applied the Weibull curve
(with cure probability) to cumulative incidence function for cancer
in the following way:
S(t) p (1 p) expt
where p is the cure rate of colon cancer [18]. Tomodel theOS curve,
e used the cure rate previously estimated by DFS data. Deaths
rom causes other than colon cancer were considered a competing
isk. After 60 months, the hazard of death from other causes was
hought to be equal to that of the general population of the same
ge. Appendix A found at doi:10.1016/j.jval.2011.10.006 provides a
detailed description of the statistical method to estimate survival
curves.
Using the estimated survival curve,meanprogression-free sur-
vival and OS were calculated by taking the area under each sur-
vival curve. We calculated the QALY gain of group i with the
ollowing equation:
iUDFS,i OiDi UDP
where Di is the mean DFS for group i, Oi is the mean OS of group i,
DFS,i is the utility score of DFS (group i), and UDP is the utility score
f disease progression.
Fig. 2 – Estimated overall survival curves. FU/LV,
5-fluorouracil/leucovorin.
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rate of colorectal cancer in Japan is lower than that of European
and North American countries, we performed sensitivity analysis
on the estimated cure rate. We increased the cure rate and re-
duced the treatment difference compared with that reported by
theMOSAIC trial. The following four parameters were also subject
to sensitivity analysis: 1) cost ofmetastasis, 2) time horizon, 3) cost
of AE, and 4) discount rate. Uncertainty of the ICER was estimated
by the bootstrap method (in which bootstrap resampling was re-
peated 10,000 times).
Results
Survival curve estimation
Estimated DFS and OS curves are shown in Figures 1 and 2. The
estimated cure rate of colon cancer was 0.715 with FOLFOX treat-
ment and 0.622 with FU/LV treatment. The estimated 5-year DFS
was 0.684 with FOLFOX and 0.619 with FU/LV, and the estimated
6-year OSwas 0.688 with FOLFOX and 0.640 with FU/LV. Estimated
mean OSwas 12.4 years (3% discount) and 17.2 years (0% discount)
with FOLFOX and 11.4 years (3% discount) and 15.8 years (0% dis-
count) with FU/LV.
Base-case analysis
Results of base-case cost-effectiveness analysis are shown inTable 2.
Expectedmedical costs of FOLFOX therapywere estimated at JPY 3.1
million (USD34,000),which increasesmedical costs by JPY1.1million
(USD 13,000) compared with FU/LV therapy (JPY 1.9 million [USD
22,000]). The mean estimated QALY was 9.83 with FOLFOX and 9.07
with FU/LV; the difference was 0.76 QALY. The ICER with FOLFOX
was JPY 1.5 million (USD 17,000) per QALY compared with FU/LV.
Results of sensitivity analysis
Wefirst changed the parameter of cure rate. Althoughwe estimated
a cure rate difference of 9.3%, we lowered this difference to 7.5% and
5%. The 7.5% difference was almost equal to the 5-year DFS differ-
Table 3 – Results of sensitivity analysis: cure rate of
colon cancer.
More conservative
(treatment
difference  7.5%)
Most conservative
(treatment
difference  5%)
FOLFOX 75% 80% 82.5% 75% 80% 82.5%
FU/LV 67.5% 72.5% 75% 70% 75% 77.5%
ICER 222 231 236 428 452 465
FU/LV, 5-fluorouracil/leucovorin; ICER, incremental cost-effective-
Table 2 – Results of cost-effectiveness analysis.
Cost Incremental cost
(JPY 10,000)
FU/LV 194 –
FOLFOX 307 113
95% CI 34 to 174
I
CI, confidence interval; FU/LV, 5-fluorouracil/leucovorin; JPY, Japanes
life-year.ness ratio.ence reported by theMOSAIC trial.Whenwe assumed that Japanese
outcomes were better than those of European and North American
countries, the cure rate difference exerted more influence on the
ICER than did the absolute cure rate. Nevertheless, in the most con-
servative setting, the ICER of FOLFOX was less than JPY 5.0 million
(USD 56,000) per QALY (Table 3).
The ICER increased with shorter time horizons and lower costs
of metastasis (Table 4). With a 10-year time horizon and meta-
static cost of JPY 1.0 million per year, the ICER increased to JPY 4.4
million (USD 49,000) per QALY. Increasing the discount rate from
0% to 6% increased the ICER from JPY 1.1 million (USD 12,000) to
JPY 2.3 million (USD 26,000) per QALY. With an additive mean AE
cost of JPY 50,000 per patient, the ICER was JPY 1.7 million (USD
19,000), but at an additive mean AE cost of JPY 200,000 per person,
the ICER increased to JPY 1.9 million (USD 21,000) per QALY. Other
parameters (such as utility scores and drug costs) had small influ-
ence on the results.
The relationship between incremental cost and incremental
effectiveness is shown in Figure 3. The cost-effectiveness accept-
ability curve is shown in Figure 4. The probability that FOLOFX is
cost-effectivewas approximately 90%when thewillingness to pay
for one QALY was JPY 5.0 million (USD 56,000).
Discussion
Our cost-effectiveness analysis showed that the ICER of FOLFOX
therapy was 1.5 million (USD 17,000) per QALY. This result was
supported by sensitivity analysis. Even if we assume that Japanese
outcomes are better than those reported by the MOSAIC trial and
when the difference between colon cancer cure rates was de-
creased to 5%, the ICER remained below 5.0 million (USD 56,000)
per QALY. AE costs, which were not included in the base-case
analysis, did not strongly influence the ICER of FOLFOX. As ex-
pected, when the time horizon was shorter (to exclude the uncer-
tainty of the distant future), the ICER increased. The ICER was
estimated at JPY 3.4 million (USD 38,000) to JPY 4.4 million (USD
49,000) per QALY depending on metastatic costs. Although this
analysis did not include indirect costs, we would surmise that the
Effectiveness
(QALY)
Incremental effectiveness
(QALY)
9.07 –
9.83 0.76
0.08 to 1.62
JPY 10,000 per QALY)
149
; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted
Table 4 – Results of sensitivity analysis: time horizon
and metastatic cost.
Cost of metastasis
(JPY 10,000 per y)
Time horizon (y)
10 15 20 30
100 444 278 216 174
150 409 257 201 161
200 375 236 184 149
250 341 216 169 137CER (
e yenJPY, Japanese yen.
259V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 5 5 – 2 6 0ICER improves because productivity loss is larger in the FU/LV
group than in the FOLFOX group.
In Japan, no consensus exists with regard to the threshold of
acceptable cost per QALY saved. The National Institute for Health
and Clinical Excellence in the United Kingdom uses a threshold
range of £20,000 to £30,000 (approximately JPY 2.5million to JPY 4.5
million) [19], and in the United States, a threshold range of USD
50,000 to USD 100,000 (JPY 4.5 million to JPY 9.0 million) is often
used. A Japanese study on willingness to pay for an additional one
QALY suggests JPY 5.0 million to JPY 6.0 million is an appropriate
threshold [20]. Considering these criteria, the ICER of FOLFOX is
thought to be acceptable.
Our parametric statistical model explicitly takes into account
the colon cancer cure rate and treats the risk of death by causes
other than colon cancer as competing risk. This model can be
applied to other cancers. Our estimated survival curves fit the non-
parametric curves well. Our analysis is based on data collected at
3 years; however, the 5-year results were published after the pres-
ent study was initiated.We estimated the 5-year DFS at 0.684 with
FOLFOX and 0.619 with FU/LV; the estimated 6-year OS was 0.692
with FOLFOXand 0.638with FU/LV. TheMOSAIC trial reported that
the 5-year DFS was 0.664 with FOLFOX and 0.589 with FU/LV, and
the estimated 6-year OS was 0.729 with FOLFOX and 0.687 with
FU/LV.
Our estimated cure rates were 0.715 (FOLFOX) and 0.622 (FU/
LV). According to the Japanese guidelines for colorectal cancer,
recurrence is 0.241 (no recurrence: 0.759) in stage IIIA and 0.408 (no
recurrence: 0.592) in stage IIIB. The MOSAIC trial included stage
IIIA and stage IIIB patients, suggesting that these estimated cure
rates are valid.
A Canadian analysis reported that the ICER of FOLFOXwasCAD
24,104 (JPY 2.0million; CAD 1 JPY 85) per QALY on the basis of the
sameMOSAIC trial [12]. This analysis was based on a 50-year time
horizon and an annual 5% discount rate applied to both outcome
and cost. A US cost-effectiveness analysis estimated the ICER at
USD 22,800 (JPY 2.1million) per QALY using a 3% discount rate [11].
These similar ICER values suggest that our analysis is robust. The
National Institute for Health and Clinical Excellence in the United
Kingdom also recommended first-line FOLFOX therapy for colon
cancer in 2006 [21].
There are several limitations of our analysis. First, we were
unable to obtain all patient-level data needed to perform eco-
nomic evaluation. For example, we used utility scores that were
aggregated data from other published articles, and data on the
consumption of 5-FU and l-LV were not available. Second, re-
source use data for treatment of AE were not known. Although
Fig. 3 – Distribution of incremental effectiveness (IE) and
incremental cost (IC). JPY, Japanese yen.costs of AEs associated with FOLFOX are higher than those of FU/
LV, we cannot include the costs in the base-case analysis. The
sensitivity analysis showed that AE costs had little influence on
the results; however, this is another limitation of our analysis.
Finally, it is possible that Japanese outcomes and resource use of
adjuvant therapy do not differ from those of the countries that
participated in the MOSAIC trial. In Japan, a phase I/II study was
conducted, but the sample size was small. Although we do not
necessarily agree with Japanese oncologists who insist that Japa-
nese outcomes are better than those of other countries, it cannot
be denied that outcomes of Japanese patients differ from those of
patients from other countries. In addition, the Japanese dose of
oxaliplatin may be smaller than the dose used in European and
North American countries because Japanese patients have a
smaller body surface area. Therefore, when FOLFOX regimens are
administered in Japan, the expected costs and ICER may be lower
than our estimation.
Simple cost cutting may hinder the development of innovative
technologies, but economic evaluation can help clarify the rela-
tionship between value and costs of various therapies to deter-
mine appropriate treatment strategies.We conclude that adjuvant
FOLFOX is cost-effective in Japan for stage III colon cancer com-
pared with FU/LV. Even when more conservative values are used
for parameters regarding the benefits of adjuvant FOLFOX, this
conclusion does not change. Adjuvant FOLFOX therapy should be
considered as a treatment option if oncologists believe that the
clinical benefits outweigh themore severe AEs compared with the
FU/LV regimen.
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